Troxerutin

DB13124

small molecule investigational

Deskripsi

Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.

Struktur Molekul 2D

Berat 742.6752
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

639 Data
Apixaban Apixaban may increase the anticoagulant activities of Troxerutin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Troxerutin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Troxerutin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Troxerutin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Troxerutin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Troxerutin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Troxerutin is combined with Obinutuzumab.
Rivaroxaban Troxerutin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Troxerutin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Troxerutin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Troxerutin.
Urokinase Urokinase may increase the anticoagulant activities of Troxerutin.
Vitamin E Vitamin E may increase the anticoagulant activities of Troxerutin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Troxerutin.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Troxerutin.
Quinine The therapeutic efficacy of Troxerutin can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Troxerutin can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Troxerutin.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Troxerutin.
Pentoxifylline The therapeutic efficacy of Troxerutin can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Troxerutin.
Levocarnitine The therapeutic efficacy of Troxerutin can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Troxerutin.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Troxerutin.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Troxerutin.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Troxerutin.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Troxerutin.
Quinestrol Quinestrol may decrease the anticoagulant activities of Troxerutin.
Hexestrol Hexestrol may decrease the anticoagulant activities of Troxerutin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Troxerutin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Troxerutin.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Troxerutin.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Troxerutin.
Zeranol Zeranol may decrease the anticoagulant activities of Troxerutin.
Equol Equol may decrease the anticoagulant activities of Troxerutin.
Methallenestril Methallenestril may decrease the anticoagulant activities of Troxerutin.
Epimestrol Epimestrol may decrease the anticoagulant activities of Troxerutin.
Moxestrol Moxestrol may decrease the anticoagulant activities of Troxerutin.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Troxerutin.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Troxerutin.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Troxerutin.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Troxerutin.
Biochanin A Biochanin A may decrease the anticoagulant activities of Troxerutin.
Formononetin Formononetin may decrease the anticoagulant activities of Troxerutin.
Estriol Estriol may decrease the anticoagulant activities of Troxerutin.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Troxerutin.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Troxerutin.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Troxerutin.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Troxerutin.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Troxerutin.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Troxerutin.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Troxerutin.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Troxerutin.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Troxerutin.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Troxerutin.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Troxerutin.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Troxerutin.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Troxerutin.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Troxerutin.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Troxerutin.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Troxerutin.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Troxerutin.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Troxerutin.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Troxerutin.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Troxerutin.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Troxerutin.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Troxerutin.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Troxerutin.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Troxerutin.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Troxerutin.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Troxerutin.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Troxerutin.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Troxerutin.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Troxerutin.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Troxerutin.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Troxerutin.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Troxerutin.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Troxerutin.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Troxerutin.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Troxerutin.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Troxerutin.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Troxerutin.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Troxerutin.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Troxerutin.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Troxerutin.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Troxerutin.
Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Troxerutin.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Elas gel
    Lotion • - • Topical • US • OTC
  • Elas gel
    Lotion • - • Topical • US • OTC

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul